Bavarian Nordic shares pop over 12% on earnings beat, bumper mpox vaccine order

Shares of a biotech company surged more than 12% after it announced strong earnings and a large vaccine order amid the ongoing mpox outbreak. The Danish company reported second quarter revenues and operating profit that exceeded analyst expectations. It also secured a contract to supply mpox and smallpox vaccines to an undisclosed European country. This order follows the World Health Organization’s declaration of mpox as a global public health emergency due to its spread from the Democratic Republic of Congo to neighboring nations.